Jeffrey A Lieberman

发表

AOT and Long-Term Use of Antipsychotics.

John A Talbott, Steven S Sharfstein, Jeffrey A Lieberman, 2016, Psychiatric services.

Brian Sheitman, Jeffrey A Lieberman, Leslie Citrome, 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Brian Sheitman, Jeffrey A Lieberman, Leslie Citrome, 2002, The American journal of psychiatry.

Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice

Jeffrey A Lieberman, Seiya Miyamoto, J. Lieberman, 2000, Neuropsychopharmacology.

Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia

Guido Gerig, Jeffrey A Lieberman, Daniel Bradford, 2005, British Journal of Psychiatry.

Physical health monitoring of patients with schizophrenia.

John M Davis, Jeffrey A Lieberman, Nancy H. Covell, 2004, The American journal of psychiatry.

Catching Up on Schizophrenia Natural History and Neurobiology

David A Lewis, Jeffrey A Lieberman, J. Lieberman, 2000, Neuron.

Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity

Jeffrey A Lieberman, J. Lieberman, B. Sheitman, 1997, Neuropsychopharmacology.

Recent advances in the neurobiology of schizophrenia.

Jeffrey A Lieberman, Seiya Miyamoto, John H Gilmore, 2003, Molecular interventions.

Prenatal and Neonatal Brain Structure and White Matter Maturation in Children at High Risk for Schizophrenia AJP in Advance

Martin Styner, Guido Gerig, Weili Lin, 2010 .

Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia

Fabio Macciardi, Steven G Potkin, Jeffrey A Lieberman, 1999, Neuropsychopharmacology.

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Jianxin Shi, Susmita Datta, Aribert Rothenberger, 2013, Nature Genetics.

Measurement of Brain Metabolites by 1H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Jeffrey A Lieberman, Robert M Hamer, R Grant Steen, 2005, Neuropsychopharmacology.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Daniel Weintraub, Jeffrey A Lieberman, Pierre N Tariot, 2006, The New England journal of medicine.

Macroscopic fast neuronal oscillations and synchrony in schizophrenia.

Aysenil Belger, Jeffrey A Lieberman, J. Lieberman, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia.

Jeffrey A Lieberman, Manzar Ashtari, Robert M Bilder, 2002, The American journal of psychiatry.

Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology.

Hongshik Ahn, Jeffrey A Lieberman, Philippe Delespaul, 2010, Schizophrenia bulletin.

Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective

Jeffrey A Lieberman, J. Lieberman, 1999, Biological Psychiatry.

Clinical Research in the Age of Neuroscience

Jeffrey A Lieberman, J. Lieberman, 2000, Neuropsychopharmacology.

Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

Jeffrey A Lieberman, Patrick F Sullivan, Robert E Vann, 2011, Neuropsychopharmacology.

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

Donard S Dwyer, Jeffrey A Lieberman, Ariel Y Deutch, 2008, Pharmacological Reviews.

Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study

Jeffrey A Lieberman, Gary G Koch, Robert A Rosenheck, 2011, Statistics in biopharmaceutical research.

Practice guideline for the treatment of patients with schizophrenia

Julie Kreyenbuhl, Jeffrey A Lieberman, Alexander L. Miller, 1997 .

Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients

Jeffrey A Lieberman, Herbert Y Meltzer, Markus M Nöthen, 1998, Neuropsychopharmacology.

Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing.

Aysenil Belger, Jeffrey A Lieberman, Diana O Perkins, 2005, Archives of general psychiatry.